The NCCN Virtual Congress: Hematologic Malignancies (#NCCNhem21) will provide the latest evidence and expert consensus on emerging practices and debates in blood cancer treatment, online Thursday, October 14, 2021 – Saturday, October 16, 2021. The NCCN Virtual Nursing Forum will be held October 8, 2021.
Newswise: Latest News
NCCN Meeting on Blood Cancers Empowers Interprofessional Care Teams
October 4, 2021By
Cancer-Killing Virus Therapy Shows Promise Against Inoperable Skin Cancers
April 23, 2021By
Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were not able to have their tumors surgically removed.
Newswise: Latest News
Evolution May Be to Blame for High Risk of Advanced Cancers in Humans
December 9, 2020By
UC San Diego researchers discovered that most people no longer produce the Siglec-12 protein, but some of those who do are at twice the risk for advanced cancer.
Newswise: Latest News
New evolution-busting drug overcomes resistance in aggressive breast cancers
October 6, 2019By
A new type of drug that blocks one of cancer’s key evolutionary escape routes from chemotherapy could be used to treat aggressive breast cancers, a new study has shown.
Latest Science News — ScienceDaily
New way to target cancer’s diversity and evolution
September 14, 2019By
Scientists have revealed close-up details of a vital molecule involved in the mix and match of genetic information within cells — opening up the potential to target proteins of this family to combat cancer’s diversity and evolution.
Latest Science News — ScienceDaily
Precision drugs could unmask cancers to immune system and boost effects of immunotherapy
March 10, 2019By
Precision cancer drugs called PARP inhibitors have a previously unknown ability to boost the immune system, and could help many more patients benefit from immunotherapy, a new study reveals.
Latest Science News — ScienceDaily
PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA mutations
August 16, 2018By
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Newswise: Latest News
First-in-Human Clinical Trial of New Targeted Therapy Drug Reports Promising Responses for Multiple Cancers
April 16, 2018By
A phase I, first-in-human study led by The University of Texas MD Anderson Cancer Center reveals for the first time, an investigational drug that is effective and safe for patients with cancers caused by an alteration in the receptor tyrosine kinase known as RET. The drug appears to be promising as a potential therapy for RET-driven cancers, such as medullary and papillary thyroid, non-small cell lung, colorectal and bile duct cancers, which have been historically difficult to treat.
Newswise: Latest News
Cancer’s Gene-Determined “Immune Landscape” Dictates Progression of Prostate Tumors
January 12, 2018By
The field of immunotherapy – the harnessing of patients’ own immune systems to fend off cancer – is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of patients, suggesting that as-yet unidentified variations among tumors result in distinct paths of disease progression and response to therapy.
Newswise: Latest News
